ABSTRACT: Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients [07/13/2001; Journal of Clinical Oncology] PURPOSE: Bisphosphonate therapy has decreased the risk of skeletal complications associated with osteolytic bone lesions in patients with breast cancer and multiple myeloma. The large prospective studies have used 21 to 24 months of treatment. We studied the safety and efficacy of bisphosphonates in a subset of patients who received therapy for more than 24 months. CONCLUSION: Prolonged treatment with the potent bisphosphonates pamidronate and zoledronic acid seems to be well tolerated and should be studied in prospective, randomized studies to document prolonged skeletal efficacy. ABSTRACT only,10/03 Nursing Guidelines: Giving Bisphosphonates J Oral Maxillofac Surg, 5/04 Avascular Necrosis of the Jaws: Risk Factor in Ca Mets Package Insert re Osteonecrosis & Bisphosphonates Risk of Ostenecrosis in Cancer Pts Summary of FDA Hearing (ODAC), March 4, 2005 Ltr to Editor: The Oncologist - From an Advocate 'Reduced' Schedule to Reduce Osteonecrosis Personal Story of Recovery from Osteonecrosis of the Jaw Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.